Thromboembolism in Anorexia Nervosa (TEAN)

October 10, 2024 updated by: Jeanie Meincke Egedal, MD, Odense University Hospital

Thromboembolism in Anorexia Nervosa: a Registry-based Study of a National Cohort and a Case-control Study of the Hemostatic Balance and Its Association with Nutritional Status, Insulin and Cortisol

BACKGROUND: Sudden death due to thromboembolic (TE) events in patients with anorexia nervosa (AN) is well known. However, the incidence of TE events and the hemostatic balance in patients with AN are sparsely investigated. Also, associations between re-nutrition and the hemostatic balance have not been studied.

OBJECTIVE: To describe the incidence of TE events in patients with AN compared to the background population, to characterize the hemostatic balance in AN compared to normal-weight women, and to assess the associations between the hemostatic balance and nutritional status, insulin sensitivity and cortisol level in women with AN.

METHODS: The incidence of TE will be described using a Danish cohort of AN patients (n=10,049) with follow-up in national registries. A comprehensive battery of hemostatic biomarkers will be compared in a case-control study of 40 patients with AN and associations between hemostasis and nutritional status will be studied.

Study Overview

Detailed Description

BACKGROUND

Anorexia nervosa (AN) is a complex psychiatric disorder with concomitant medical complications to malnutrition and starvation and it is associated with the highest mortality of the mental illnesses.

It is estimated that one-third of all deaths in patients with AN are due to cardiac causes, mainly sudden death, and alterations in cardiac electrical activity, structure and hemodynamics have been suggested as mortality causes. Thrombotic disorders such as myocardial infarction, stroke, and pulmonary embolism may also result in sudden cardiac death, and the investigators have previously reported venous thromboembolism in four patients with AN

Whether a disturbed hemostatic balance is associated with re-nutrition, insulin sensitivity and cortisol in AN is unknown. The guidelines of thromboprophylaxis treatment may not be appropriate in this patient group due to metabolic and hemostatic disturbances and increased thrombotic risk of reasons related to refeeding syndrome not listed in current guidelines. To optimize guidelines for AN patients, new evidence is highly warranted

AIMS

This study aims to determine the incidence of venous and arterial thromboembolic events in patients with AN compared to the background population, to characterize the hemostatic balance in AN compared to normal-weight women, and to assess the associations between the hemostatic balance and nutritional status, insulin sensitivity and cortisol level in women with AN. The study will provide new knowledge which qualifies the work of preparing guidelines for thrombosis prophylactic intervention in this patient group.

RESEARCH QUESTIONS

  1. Is the incidence of venous and arterial thromboembolism increased in patients diagnosed with AN compared to an age-matched control group?
  2. Is the hemostatic balance disturbed in women with AN compared with healthy, normal-weight women?
  3. Are cortisol, insulin sensitivity and nutritional status associated with alterations in biomarkers of the hemostatic balance in AN?

The research questions will be answered in three sub studies.

SUB STUDY 1

Sub study 1 will answer research question 1, determining if the incidence of venous and arterial thromboembolism is increased in patients with AN compared to an age-matched control group. The study is based on the comprehensive Danish registries. An already existing cohort of more than 10,000 patients with AN will be evaluated for incidence of thromboembolic events and compared to an age-matched control group.

SUB STUDY 2

Sub study 2 will answer research question 2, exploring the hemostatic balance in patients with AN compared to healthy, normal-weight controls.

Patients with anorexia nervosa (n=40) will be recruited from the highly specialized Center of Eating Disorders at Odense University Hospital. Patients and controls will have blood samples drawn to evaluate the hemostatic balance using a large battery of hemostatic markers.

SUB STUDY 3

Sub study 3 will answer research question 3, clarifying associations between the hemostatic balance and cortisol, insulin sensitivity and nutritional status in AN. Participants of sub study 3 are the patients with AN from sub study 2. From further analysis of the blood samples and by answering validated questionnaires to determine nutritional status and AN severity, research question 3 will be answered.

Study Type

Observational

Enrollment (Actual)

80

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Fyn
      • Odense, Fyn, Denmark, 5000
        • Clinical Pharmacology and Pharmacy, University of Southern Denmark
      • Odense, Fyn, Denmark, 5000
        • Department of Child and Adolescent Mental Health Odense, Mental Health Services in the Region of Southern Denmark
      • Odense, Fyn, Denmark, 5220
        • The Nutritional Unit, Department of Endocrinology, Center for Eating Disorders, Odense University Hospital and Psychiatry in the region of Southern Denmark
    • Jylland
      • Esbjerg, Jylland, Denmark, 6700
        • Unit for Thrombosis Research, Department of Clinical Biochemistry, Hospital of South West Jutland
    • Västerbotten
      • Umeå, Västerbotten, Sweden
        • Department of Clinical Sciences, Umeå University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 46 years (Adult)

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Patients with anorexia nervosa and healthy, age-matched controls.

Description

Inclusion Criteria, patients:

  • Fulfilling Diagnostic and Statistical Manual V (DSM-5) criteria for AN
  • Age 18 - 50 years
  • Female sex

Exclusion Criteria, patients:

  • Somatic comorbidity requiring systemic medications
  • Previous thromboembolic event and/or known genetic predisposition
  • Use of p.o. hormonal contraception
  • Smoking

Inclusion Criteria, controls:

  • BMI 18.5 - 25.0
  • Age 18 - 50 years
  • Female sex

Exclusion Criteria, controls:

  • Somatic comorbidity requiring systemic medications
  • Previous thromboembolic event and/or known genetic predisposition
  • Use of p.o. hormonal contraception
  • Smoking

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Patients
Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
Hemostatic biomarkers
Eating Disorder Inventory - third version (EDI-3) Eating Disorder Quality of Life Scale (EDQLS)
Controls
Will have thromboembolic incidence rate evaluated and will have a battery of hemostatic markers analyzed
Hemostatic biomarkers

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of thromboembolic events
Time Frame: Data on thromboembolic events are collected from health registries. Data is collected through study completion of the time frame in the registry, up to 26 years.
Arterial and venous thrombosis. Non-fatal outcomes of a thromboembolic event will be validated by the use of anticoagulants in the period immediately after the outcome defining event.
Data on thromboembolic events are collected from health registries. Data is collected through study completion of the time frame in the registry, up to 26 years.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemostatic balance
Time Frame: The study is cross-sectional. Time frame for completion of participation in the study is 1 day.

Evaluation of differences of measurements of hemostatic biomarkers in patients with AN compared to healthy controls.

Hemostatic biomarkers that will be evaluated:

Tissue factor TF:Ag, pg/mL

Contact activation (descriptive, system is assessed)

Fibrinogen mg/dl

Thrombin generation (descriptive)

Prothrombin fragment 1+2 pmol/L

Plasminogen activator inhibitor type 1 ng/mL

Tissue plasminogen activator ng/mL

Fibrin clot properties (descriptive, using turbidity measurements)

The study is cross-sectional. Time frame for completion of participation in the study is 1 day.
Rotational Thromboelastometry (ROTEM)-variables
Time Frame: The study is cross-sectional. Time frame for completion of participation in the study is 1 day.
Evaluation of differences in ROTEM-variables in patients with AN compared to healthy controls.
The study is cross-sectional. Time frame for completion of participation in the study is 1 day.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 15, 2022

Primary Completion (Actual)

October 10, 2024

Study Completion (Actual)

October 10, 2024

Study Registration Dates

First Submitted

October 5, 2022

First Submitted That Met QC Criteria

October 10, 2022

First Posted (Actual)

October 12, 2022

Study Record Updates

Last Update Posted (Actual)

October 15, 2024

Last Update Submitted That Met QC Criteria

October 10, 2024

Last Verified

October 1, 2024

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Anorexia Nervosa

Clinical Trials on Blood samples

Subscribe